FI106201B - Menetelmä substituoidun triatsolin sulfaattisuolan valmistamiseksi - Google Patents

Menetelmä substituoidun triatsolin sulfaattisuolan valmistamiseksi Download PDF

Info

Publication number
FI106201B
FI106201B FI945694A FI945694A FI106201B FI 106201 B FI106201 B FI 106201B FI 945694 A FI945694 A FI 945694A FI 945694 A FI945694 A FI 945694A FI 106201 B FI106201 B FI 106201B
Authority
FI
Finland
Prior art keywords
formula
salt
solution
compound
sodium
Prior art date
Application number
FI945694A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945694L (fi
FI945694A0 (fi
Inventor
Leslie J Street
Raymond Baker
Victor G Matassa
Alexander R Guiblin
Carole Olive
Kendal G Pitt
David E Storey
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211903A external-priority patent/GB9211903D0/en
Priority claimed from GB939307306A external-priority patent/GB9307306D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of FI945694L publication Critical patent/FI945694L/fi
Publication of FI945694A0 publication Critical patent/FI945694A0/fi
Application granted granted Critical
Publication of FI106201B publication Critical patent/FI106201B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
FI945694A 1992-06-05 1994-12-02 Menetelmä substituoidun triatsolin sulfaattisuolan valmistamiseksi FI106201B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9211903 1992-06-05
GB929211903A GB9211903D0 (en) 1992-06-05 1992-06-05 Pharmaceutical composition
GB9301132 1993-01-21
GB939307306A GB9307306D0 (en) 1993-04-07 1993-04-07 Therapeutic agents
GB9307306 1993-04-07
PCT/GB1993/001132 WO1993025547A1 (en) 1992-06-05 1993-05-28 The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy

Publications (3)

Publication Number Publication Date
FI945694L FI945694L (fi) 1994-12-02
FI945694A0 FI945694A0 (fi) 1994-12-02
FI106201B true FI106201B (fi) 2000-12-15

Family

ID=26301005

Family Applications (3)

Application Number Title Priority Date Filing Date
FI945694A FI106201B (fi) 1992-06-05 1994-12-02 Menetelmä substituoidun triatsolin sulfaattisuolan valmistamiseksi
FI20001776A FI20001776A7 (fi) 1992-06-05 2000-08-10 Menetelmä farmaseuttisen koostumuksen valmistamiseksi
FI20001777A FI20001777L (fi) 1992-06-05 2000-08-10 Substituoidun triatsolin sulfaattisuola ja sen farmaseuttisia koostumuksia

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20001776A FI20001776A7 (fi) 1992-06-05 2000-08-10 Menetelmä farmaseuttisen koostumuksen valmistamiseksi
FI20001777A FI20001777L (fi) 1992-06-05 2000-08-10 Substituoidun triatsolin sulfaattisuola ja sen farmaseuttisia koostumuksia

Country Status (27)

Country Link
US (1) US5527817A (cs)
EP (1) EP0573221B1 (cs)
JP (2) JP2619197B2 (cs)
KR (1) KR100286411B1 (cs)
CN (1) CN1043532C (cs)
AT (1) ATE165602T1 (cs)
AU (2) AU4337293A (cs)
BG (1) BG61976B1 (cs)
CA (1) CA2097208C (cs)
CZ (1) CZ282060B6 (cs)
DE (1) DE69318212T2 (cs)
DK (1) DK0573221T3 (cs)
ES (1) ES2116411T3 (cs)
FI (3) FI106201B (cs)
HK (1) HK1010050A1 (cs)
HU (1) HUT71403A (cs)
IL (1) IL105847A (cs)
LV (1) LV12210B (cs)
MX (1) MX9303373A (cs)
NO (1) NO307420B1 (cs)
NZ (1) NZ253210A (cs)
RO (1) RO114326B1 (cs)
RU (1) RU2130022C1 (cs)
SG (1) SG50406A1 (cs)
SK (1) SK279211B6 (cs)
UA (1) UA27908C2 (cs)
WO (1) WO1993025547A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318212T2 (de) * 1992-06-05 1998-11-19 Merck Sharp & Dohme Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
ATE207485T1 (de) * 1995-07-11 2001-11-15 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
ES2234324T3 (es) 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
WO2007054979A1 (en) * 2005-11-14 2007-05-18 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2017130141A1 (en) 2016-01-27 2017-08-03 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2024144413A1 (ru) * 2022-12-28 2024-07-04 Общество С Ограниченной Ответственностью "Ферринг Продакшн" Жидкая фармацевтическая композиция для назального введения, содержащая ризатриптан

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528319A3 (ru) * 1985-07-23 1989-12-07 Глэксо Груп Лимитед (Фирма) Способ получени производных имидазола или их физиологически приемлемых солей
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE69026759D1 (de) * 1989-07-03 1996-06-05 Yoshitomi Pharmaceutical Benzazin-Verbindungen und deren pharmazeutische Verwendungen
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
DE69318212T2 (de) * 1992-06-05 1998-11-19 Merck Sharp & Dohme Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie

Also Published As

Publication number Publication date
CZ282060B6 (cs) 1997-05-14
EP0573221A1 (en) 1993-12-08
US5527817A (en) 1996-06-18
KR100286411B1 (ko) 2001-04-16
FI20001777A7 (fi) 2000-08-10
JP2619197B2 (ja) 1997-06-11
DE69318212T2 (de) 1998-11-19
FI20001777L (fi) 2000-08-10
JPH09176155A (ja) 1997-07-08
KR950701922A (ko) 1995-05-17
NO944656L (no) 1994-12-02
FI20001776L (fi) 2000-08-10
SK147994A3 (en) 1995-07-11
BG99132A (bg) 1995-07-28
SK279211B6 (sk) 1998-08-05
BG61976B1 (bg) 1998-11-30
RU94046380A (ru) 1996-12-10
DK0573221T3 (da) 1998-10-07
NO307420B1 (no) 2000-04-03
SG50406A1 (en) 1998-07-20
FI945694L (fi) 1994-12-02
DE69318212D1 (de) 1998-06-04
AU3987593A (en) 1993-12-09
RO114326B1 (ro) 1999-03-30
ATE165602T1 (de) 1998-05-15
NZ253210A (en) 1995-09-26
JP2972150B2 (ja) 1999-11-08
AU659311B2 (en) 1995-05-11
UA27908C2 (uk) 2000-10-16
CZ304494A3 (en) 1995-09-13
HU9403478D0 (en) 1995-02-28
CN1043532C (zh) 1999-06-02
IL105847A (en) 1998-09-24
IL105847A0 (en) 1993-09-22
LV12210B (en) 1999-03-20
FI945694A0 (fi) 1994-12-02
CA2097208A1 (en) 1993-12-06
AU4337293A (en) 1994-01-04
FI20001776A7 (fi) 2000-08-10
RU2130022C1 (ru) 1999-05-10
LV12210A (lv) 1999-01-20
ES2116411T3 (es) 1998-07-16
HK1010050A1 (en) 1999-06-11
EP0573221B1 (en) 1998-04-29
CN1089263A (zh) 1994-07-13
CA2097208C (en) 2005-02-08
WO1993025547A1 (en) 1993-12-23
MX9303373A (es) 1995-01-31
NO944656D0 (no) 1994-12-02
JPH0641121A (ja) 1994-02-15
HUT71403A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
EP0490689B1 (en) 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate (2:1)
FI106201B (fi) Menetelmä substituoidun triatsolin sulfaattisuolan valmistamiseksi
HK1010050B (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
CA2225416C (en) A triazolylmethyl-indole ethylamine bisulfate salt
PL174489B1 (pl) Siarczan N,N-dimetylo-2-[5-(1,2,4-triazol-1-ilometylo)-1H-indol-3-ilo]etyloaminy, zawierający go preparat farmaceutyczny oraz sposób wytwarzania korzystnej farmaceutycznie soli N,N-dimetylo-2-[5-(1,2,4-triazol-1-ilometylo)-1H-indol-3-ilo]etyloaminy